The aim of this study is to evaluate the impact of interferon beta (IFN-β) therapy on CSF levels of Nf-L, Nf-H, and CHI3L1 in early relapsing–remitting MS (RRMS) and assess their association with long-term clinical outcomes and MRI activity. Here, CHI3L1 is linked to relapsing-remitting multiple sclerosis.